Guggenheim Raises Tenet Healthcare (THC) Price Target to $307

Guggenheim has reaffirmed its Buy rating for Tenet Healthcare Corporation (NYSE: THC) and raised its price target to $307 from $283 as of October 16, 2026. The stock was trading at approximately $274.62 on the same day, showing potential for upside based on the new target.

Guggenheim's Call on Tenet Healthcare

Guggenheim maintained its positive outlook on Tenet Healthcare, citing the company's solid position within the healthcare services sector. The updated price target of $307 reflects confidence in Tenet's operational capacity and market opportunities. This marks an increase in target expectations, potentially suggesting better performance ahead.

Other Institutional Activity in Tenet Healthcare

Several other institutional investors have recently adjusted their positions in Tenet Healthcare. Blackrock Inc. grew its holdings by 38,301 shares, bringing its total to about 8.74 million shares worth approximately $2.34 billion. Price (T. Rowe) Associates Inc. added 438,363 shares, ending with about 7.96 million shares valued at around $2.13 billion. Boston Partners increased its stake by 598,273 shares, totaling roughly 4.43 million shares worth about $1.19 billion. Vanguard Portfolio Management LLC, however, reduced its holdings by 78,563 shares, bringing its total down to approximately 4.24 million shares worth about $1.13 billion. FMR, LLC saw a significant decrease, selling 3.78 million shares, which left it with about 3.99 million shares valued at around $1.07 billion.

Tenet Healthcare Corporation Stock Up 4.8%

Tenet Healthcare shares are currently trading at $274.62, which is below the new target of $307 but close to its 52-week high of $283.05. The stock's recent performance and Guggenheim's target adjustment could indicate optimistic market sentiment surrounding Tenet's growth potential. With a forward P/E ratio of 12.4, the company is positioned in a competitive sector where valuation matters.

Recent Earnings

For the fiscal year ending December 31, 2025, Tenet reported revenue of approximately $21.81 billion, reflecting a year-over-year growth of 6.8%. The company posted an EPS of $25.86 and a net margin of about 10.3%, indicating solid profitability. Tenet's next earnings report is scheduled for October 27, 2026, which will provide additional insights into its performance.

Insider Buying and Selling at Tenet Healthcare Corporation

Several insiders have sold shares recently. Director Kerrey Joseph Robert sold 12,010 shares valued at about $3.17 million on September 14, 2026. Mark Richard J, also a Director, sold 10,000 shares for around $2.63 million on September 10, 2026. Director West Nadja Y. sold 1,152 shares priced at $258.80, totaling approximately $298,138 on September 2, 2026. Chief Operating Officer Lisa Y Foo sold 24,000 shares at an average price of $266.32, amounting to about $6.39 million on August 31, 2026.

Analysts Set New Price Targets

Along with Guggenheim's updated target, BMO Capital initiated coverage with a Market Perform rating and a target of $265 on September 23, 2026. Leerink Partners maintained an Outperform rating with a target of $309, while Wells Fargo kept its Overweight rating, adjusting the target to $281 from $231 on August 3, 2026. Truist Securities maintained their Buy rating with a target of $290. The consensus price target for Tenet across 21 analysts stands at approximately $285.57.

About Tenet Healthcare

Tenet Healthcare Corporation is a diversified healthcare services company based in Dallas, Texas. It operates hospitals and outpatient facilities, providing a range of services including acute care, surgical procedures, and diagnostic services. The company's recent performance and growth potential have drawn attention from analysts, contributing to the positive sentiment surrounding its stock.

Bottom Line

Investors should keep an eye on Tenet Healthcare's upcoming earnings report on October 27, 2026, for further insights into its financial health. The latest adjustments in analyst ratings reflect a positive outlook, but remember that the 13F filings are backward-looking and may not represent current positions.